Observation of Medical Treatments in MBC HER2-negative Patients (AMBRA)

June 14, 2016 updated by: Consorzio Oncotech

Evaluation of Medical Treatments in MBC HER2 Negative Patients in Italy - Observational Study

While therapeutic strategies for HER2-positive breast cancer are well defined, there is not a standard strategy for HER2-negative tumors.

Because of lack of information related to the the factors affecting the choice of a particular treatment strategy, as well as the optimization of the correct sequence of treatments, the choice of the treatment for the advanced disease remains highly empirical and may differ significantly among the different cancer centers.

The purpose of this study is the observation of a cohort of patients with metastatic HER2-negative in terms of:

  1. the choice of chemotherapy treatments starting from the first line of treatment;
  2. factors that may influence these choices;
  3. correlation among the characteristics of patients (age, menopausal status, etc.) and type of adjuvant and metastatic treatment ;
  4. clinical outcome (pattern of relapse, time from diagnosis, etc.);
  5. evaluation of the adherence to the literature's recommendations for therapeutic sequences in clinical practice.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

In particular, the attention will be on those factors, largely discussed in the literature, that predominantly guide the choice among different therapeutic approaches such as:

  • metastatic sites;
  • hormone receptor status;
  • disease-free interval;
  • grading;
  • response to a previous treatment with hormonal therapy or chemotherapy. The primary objective is the description of medical therapeutic strategies for the first, the second and the subsequent lines of chemotherapy in a cohort of patients with HER2-negative metastatic breast cancer and the evaluation of the possible correlation between the choice of treatment, in the adjuvant phase or for the metastatic disease and also for the patients' characteristics (age, menopausal status, comorbidity).

the secondary objectives are:

  • Analyze the "Time to Treatment Change", defined as the interval of time that elapses from the start of chemotherapy to the discontinuation or the occurrence of any other event. This finding is of a particular clinical relevance, since randomized trials using the "Time To Progression" (TTP) as a measure of effectiveness of the treatment in the study, but this time parameter may not correspond to what is observed in clinical practice, where the revaluations of disease are not conducted at preset intervals as is in the case of controlled clinical trials.
  • Evaluate the correlation between the characteristics of the patients and the choice of the type of chemotherapy.
  • Assess the potential correlation between the type of adjuvant therapy and the type of response obtained with the first-line treatment and between the answer to this last therapy line and second/third one.
  • Assess the adherence to the literature's recommendations (Consensus Conferences and Guide-lines) of the choices between the sequential therapy vs the combination therapy in different lines of treatment (first, second, third line) of the metastatic disease.

Study Type

Observational

Enrollment (Anticipated)

1500

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: MD

Study Contact Backup

Study Locations

  • Italy
      • Monza, Italy, 20900
        • Recruiting
        • A.O. San Gerardo
        • Contact:
        • Principal Investigator:
          • Marina Elena Cazzaniga, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Sampling Method

Non-Probability Sample

Study Population

Female patients from Italy with metastatic breast cancer.

Description

Inclusion Criteria:

  1. Patients with HER2-negative metastatic breast cancer (Stage IV), that have received or not the endocrine therapy for the metastatic disease and that are candidate for the first-line chemotherapy treatment in the years 2014-2015 (prospective cohort), or patients that have received a treatment of first, second or subsequent-line of chemotherapy for the metastatic disease in the years 2012-2013 (retrospective cohort).
  2. Age > 18 years

  3. Availability of all information required by the study, in particular:

    • histology
    • hormone receptor status
    • grading
    • stage of disease at diagnosis
    • type of surgery for the primary tumor
    • type of adjuvant therapy (chemotherapy or hormone therapy)
    • type of medication received as adjuvant therapy
    • date and seat of the relapse
    • type of treatment received for the first / second / third-line of treatment of metastatic disease (chemotherapy or hormone therapy)
    • type of chemotherapy regimen used and details about the medication, date and seat of disease progression
  4. Written informed consent (in case of the impossibility to obtain the consent in writing, eg, death of the patient, the data will be collected as required by the Guarantor, OJ N.72 of March 26, 2012)

Exclusion Criteria:

  1. Patients with metastatic disease at diagnosis
  2. Patients with HER2-positive breast
  3. Participation in clinical research protocols, both for the retrospective cohort and for the perspective one

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Prospective
Observation of treatment management of patients with metastatic breast cancer that have been treated or not with hormonal therapy and candidate for a first line chemotherapeutic treatment in the years 2014-2015 will be observed until the end of the study.
Other: Observation of treatment management
Group/cohort
Retrospective
Observation of treatment management of patients with metastatic breast cancer that have been treated with a first, second or following line of chemotherapeutic treatment for metastatic disease in the years 2012-2013.
Other: Observation of treatment management
Group/cohort

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number subsequent lines of treatment.
Time Frame: Outcome 1 assessed up to 24 months (2012 until 2016 where applicable)
Evaluation of correlation between treatment choice and patient characteristic ( age, menopausal status, comorbidity).
Outcome 1 assessed up to 24 months (2012 until 2016 where applicable)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time to Treatment Change
Time Frame: Outcome 2 assessed up to 24 months (2012 until 2016 where applicable)
evaluation of the time interval between the begin of chemotherapic treatment and its interruption.
Outcome 2 assessed up to 24 months (2012 until 2016 where applicable)
Correlation between the type of adjuvant therapy and the type of response to the treatment
Time Frame: Outcome 3 assessed up to 24 months (2012 until 2016 where applicable)
Outcome 3 assessed up to 24 months (2012 until 2016 where applicable)
Evaluation of the adherence to the Consensus Conferences and Guidelines concerning the choice between the sequential therapies versus the combination therapies ( first, second, third line)
Time Frame: Outcome 4 assessed up to 24 months (2012 until 2016 where applicable)
Outcome 4 assessed up to 24 months (2012 until 2016 where applicable)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Consorzio Oncotech

Collaborators

Clinical Research Technology S.r.l.

Investigators

  • Principal Investigator: Marina Cazzaniga, MD, Azienda Ospedaliera San Gerardo-Oncologia Medica (Saint Gerard Hospital-Medical Oncology)

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

May 1, 2015

Primary Completion (Anticipated)

December 1, 2016

Study Completion (Anticipated)

December 1, 2017

Study Registration Dates

First Submitted

December 15, 2014

First Submitted That Met QC Criteria

February 18, 2015

First Posted (Estimate)

February 19, 2015

Study Record Updates

Last Update Posted (Estimate)

June 15, 2016

Last Update Submitted That Met QC Criteria

June 14, 2016

Last Verified

June 1, 2016

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • GIM13-AMBRA

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Metastatic Breast Cancer

Clinical Trials on Observation of treatment management

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ecuador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe